Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-Current Assets for 7 consecutive years, with $111.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 19.66% to $111.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $590.6 million, a 97.94% increase, with the full-year FY2024 number at $125.5 million, up 189.71% from a year prior.
  • Non-Current Assets was $111.6 million for Q3 2025 at 4D Molecular Therapeutics, down from $170.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $183.2 million in Q1 2025 to a low of $5.6 million in Q1 2021.
  • A 5-year average of $74.0 million and a median of $67.5 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 1612.9% in 2021, then plummeted 57.48% in 2022.
  • 4D Molecular Therapeutics' Non-Current Assets stood at $97.2 million in 2021, then crashed by 57.48% to $41.3 million in 2022, then increased by 4.76% to $43.3 million in 2023, then skyrocketed by 189.71% to $125.5 million in 2024, then dropped by 11.04% to $111.6 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Non-Current Assets are $111.6 million (Q3 2025), $170.4 million (Q2 2025), and $183.2 million (Q1 2025).